Figure 4.

Addition of PD-1 or TIM-3 Blocking Antibody to VSV-hgp100+ACT Therapy Does Not Improve Treatment Outcomes

(A) Mice were challenged with i.v. tumor only. The mice were treated with Pmel ACT on day 7 or 8, a second treatment was delivered on day 21. Beginning on day 8 or 9, and continuing three times per week, the mice received a total of nine doses of VSV-hgp100 or PBS. The mice received six doses of isotype antibody control or immune checkpoint inhibitor beginning with the third dose of VSV (day 14–17). The antibody was delivered on the same day, after VSV administration. n = 10 mice/group. (B) Mice were challenged with i.v. B16 tumor and treated with PD-1 inhibitor. (C) Mice were challenged with i.v. B16-OVA tumor and treated with PD-1 inhibitor. (D) Mice were challenged as in (A), but treated with TIM-3 inhibitor. The significance for overall survival was determined at p < 0.008.